These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25662368)

  • 21. Intermittent parathyroid hormone therapy to increase bone formation.
    Thomas T
    Joint Bone Spine; 2006 May; 73(3):262-9. PubMed ID: 16563840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
    Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New anabolic agents in the treatment of osteoporosis.
    Hough S
    S Afr Med J; 2003 Oct; 93(10):754-6. PubMed ID: 14652963
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging anabolic treatments in osteoporosis.
    Mosekilde L; Tørring O; Rejnmark L
    Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Control of bone remodeling by bone anabolic drugs.].
    Takeuchi Y
    Clin Calcium; 2017; 27(12):1767-1774. PubMed ID: 29179172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Summary--curing osteoporosis.
    Cummings S
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):409. PubMed ID: 15758284
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.
    Garcés C; García LE
    Maturitas; 2006 Apr; 54(1):47-54. PubMed ID: 16257150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR; Bilezikian JP
    Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone.
    Goltzman D
    Arch Biochem Biophys; 2008 May; 473(2):218-24. PubMed ID: 18358824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
    McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
    Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preactivation of β-catenin in osteoblasts improves the osteoanabolic effect of PTH in type 1 diabetic mice.
    Chen S; Yang L; He S; Yang J; Liu D; Bao Q; Qin H; Du W; Zhong X; Chen C; Zong Z
    J Cell Physiol; 2020 Feb; 235(2):1480-1493. PubMed ID: 31301073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of parathyroid hormone in the management of osteoporosis.
    Rosen CJ
    Horm Res; 2005; 64 Suppl 2():81-5. PubMed ID: 16286779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anabolic effects of parathyroid hormone.
    Rubin MR; Cosman F; Lindsay R; Bilezikian JP
    Osteoporos Int; 2002; 13(4):267-77. PubMed ID: 12030541
    [No Abstract]   [Full Text] [Related]  

  • 37. Anabolic agents and bone quality.
    Sibai T; Morgan EF; Einhorn TA
    Clin Orthop Relat Res; 2011 Aug; 469(8):2215-24. PubMed ID: 21132409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New understanding and treatments for osteoporosis.
    Mazziotti G; Bilezikian J; Canalis E; Cocchi D; Giustina A
    Endocrine; 2012 Feb; 41(1):58-69. PubMed ID: 22180055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of osteoporosis: role of bone-forming agents.
    Reginster JY; Halkin V; Henrotin Y; Gosset C
    Osteoporos Int; 1999; 9 Suppl 2():S91-6. PubMed ID: 10525731
    [No Abstract]   [Full Text] [Related]  

  • 40. Treating osteoporosis by targeting parathyroid hormone to bone.
    Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
    Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.